Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Robert "Bob" Swanson (1947–1999) was an American venture capitalist who co-founded Genentech in 1976 with Herbert Boyer. Genentech is one of the leading biotechnology companies in the world. He was CEO of Genentech from 1976 to 1990, and chairman from 1990 to 1996.
Pages in category "Drugs developed by Genentech" The following 102 pages are in this category, out of 102 total. This list may not reflect recent changes. A.
Well, when we published the price list of what started as 100-plus drugs and now is 2,500 medications, all of a sudden there was a benchmark that everybody could compare.
Herbert Wayne "Herb" Boyer (born July 10, 1936) is an American biotechnologist, researcher and entrepreneur in biotechnology. Along with Stanley N. Cohen and Paul Berg, he discovered recombinant DNA, a method to coax bacteria into producing foreign proteins, which aided in jump-starting the field of genetic engineering.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening ...
In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees. [21] In 2015 Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma. [22] In March 2016 Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib. [23]
That being said, a new report by Evaluate, a market research business, supports the idea that it'll be Novo Nordisk leading the market for weight loss drugs in 2030.